Non-small cell lung cancer (NSCLC)
Showing 1 - 25 of >10,000
NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- MK-2870
- +2 more
- (no location specified)
Oct 3, 2023
NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)
Not yet recruiting
- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- (no location specified)
Aug 27, 2023
Non-Small-Cell Lung Cancer Trial in Guangzhou (PLB1004)
Recruiting
- Non-Small-Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaGuangdong General Hospital
Aug 25, 2023
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
NSCLC Without Mutation in Epidermal Growth Factor Receptor (Disorder) Trial (tereotactic body radiotherapy)
Not yet recruiting
- Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)
- tereotactic body radiotherapy
- (no location specified)
Dec 1, 2023
NSCLC Trial in Shanghai (WX-0593)
Active, not recruiting
- Non-small Cell Lung Cancer
-
Shanghai, ChinaShanghai Jiao Tong University Chest Hospital
Mar 24, 2023
Lung Cancer, NSCLC Trial (Lorlatinib, Cisplatin or Carboplatin, Pemetrexed)
Not yet recruiting
- Lung Cancer
- Non-small Cell Lung Cancer
- Lorlatinib
- +2 more
- (no location specified)
Jul 7, 2023
NSCLC Trial in Liège (induced sputum, lung biopsy, bronchoalveolar lavage)
Recruiting
- Non-small Cell Lung Cancer
- induced sputum
- +3 more
-
Liège, BelgiumCHU de Liège
Nov 7, 2022
NSCLC, NSCLC, PD-1 Trial in Beijing (F520, Pemetrexed, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- +2 more
- F520
- +3 more
-
Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Feb 22, 2023
NSCLC Trial in Changsha (Sugemalimab and Chemotherapy)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Sugemalimab and Chemotherapy
-
Changsha, ChinaHunan Cancer Hospital
Jul 7, 2023
Iruplinalkib in Treatment of ALK-Positive Non-Small Cell Lung
Recruiting
- Non-small Cell Lung Cancer (NSCLC)
-
Jinan, Shandong, ChinaShandong Cancer Hospital and Institute
Aug 8, 2023
NSCLC Trial in Iowa City (Durvalumab, Pharmacological ascorbate, Surgery (SOC))
Not yet recruiting
- Non-small Cell Lung Cancer
- Durvalumab
- +2 more
-
Iowa City, IowaUniversity of Iowa
Oct 10, 2023
Non Small Cell Lung Cancer, NSCLC, Lung Cancer Trial in Port Saint Lucie, Greenville (BL-B01D1)
Recruiting
- Non Small Cell Lung Cancer
- +2 more
-
Port Saint Lucie, Florida
- +1 more
Aug 11, 2023
Information Available in Chinese Non-Small-cell Lung Cancer
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
-
Shanghai, Shanghai, ChinaDepartment of Oncology, Shanghai pulmonary hospital
Feb 1, 2023
NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer
- Tiragolumab
- +3 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Feb 16, 2023
Advanced NSCLC Trial (fianlimab, cemiplimab, Placebo)
Not yet recruiting
- Advanced Non-Small Cell Lung Cancer
- fianlimab
- +2 more
- (no location specified)
Mar 27, 2023
NSCLC Metastatic Trial in La Jolla (Nivolumab + Plinabulin)
Active, not recruiting
- Non-small Cell Lung Cancer Metastatic
- Nivolumab + Plinabulin
-
La Jolla, CaliforniaUC San Diego Moores Cancer Center
Nov 21, 2022
NSCLC Trial in Houston (Amivantamab, Tepotinib)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
China With Non-Small-Cell Lung Cancer That is Unable to be
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- (no location specified)
May 16, 2023
NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)
Not yet recruiting
- Non-Small Cell Lung Cancer(NSCLC)
- WX-0593 Tablets
-
Jinan, Shandong, ChinaShandong Cancer Hospital and Institute
Mar 1, 2023